Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Noglux
- Development stage
- Unknown
- Lead developer
- Bioksan
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
Noglux is a multi-ingredient dietary supplement developed by Bioksan for metabolic support and glycemic control. It is formulated with a standardized white mulberry (*Morus alba*) leaf extract (Reducose) containing 1-deoxynojirimycin, a competitive alpha-glucosidase inhibitor that slows carbohydrate absorption. The formulation also includes fenugreek (*Trigonella foenum-graecum*) extract (an AMPK activator), inulin, *Lactiplantibacillus plantarum* A7 (probiotic), niacin, chromium, and zinc. Noglux is clinically evaluated for reducing insulin resistance and improving cardiovascular risk profiles in patients with prediabetes, polycystic ovary syndrome (PCOS), obesity, and postprandial reactive hypoglycemia.
- Brand names
- Noglux
- Other names
- white mulberry leaf nutraceuticalwhite mulberry leaf-based nutraceutical
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)Sucrase-Isomaltase
Beyond the preview
Go deeper on Noglux.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Noglux.